Syngene

Early enactment would compel the US biotech/pharma industry to cut reliance on China

Sai Life Sciences: Strong start keeps CDMO business in the lead

India’s limited share in the CRDMO market presents strong headroom for growth

Syngene: How soon can it overcome near-term worries?

The CRDMO player is still to see the full impact of the client’s inventory rationalisation

Syngene: Growth trajectory to moderate in FY26

The operating environment for the global CRDMO industry remains challenging

Syngene: US acquisition underlines welcome tweak in business model

Acquisition of Emergent Manufacturing Operations Baltimore LLC facility ensures proximity to one of the innovation hubs in the US, which is critical for a CRDMO player.

Syngene acquires first manufacturing site in US

Syngene USA Inc, a wholly-owned subsidiary of the company, has acquired the site from Emergent Manufacturing Operations Baltimore, LLC

Syngene: Conversion of pilot projects to long-term contracts a big positive

The company remains a strong play on the global China-switch strategy

Syngene shares slide over 4% on guidance cut as demand revival looks delayed

"Despite the challenges faced in the first half of the year, the company expects to close the full year with single-digit revenue growth and a flat PAT. EBITDA guidance remains unchanged," the statement by Syngene said.

Sai Life Sciences: Differentiated CRDMO business model to help during Trump 2.0

Globally, more than 50 percent of the research and development (R&D) spending is done in nine select pharma hubs, and, hence, it is rewarding to have a presence in these locations.

What’s the importance of US Biosecure Act for India?

The legislation will curb the dominance of Chinese players in the US biotech industry, throwing up opportunities for Indian companies

Syngene: Strong play on ‘China Switches’ in the CRAMS space

The shift in global supply chains in the post-pandemic world –described as China Switches by the company – has led to the setting up of pilot projects across a broad range of services.

Syngene: The preferred pick for sector re-allocation

This strong CRAMS play can benefit from the easing funding crisis in the biotech industry, and the shift in global supply chains, in the post-pandemic world

Weekly Tactical Pick: China+1 trend to enhance earnings visibility for this CRAMS player

Fundamentals are improving for Syngene while the stock is in a consolidation phase

High single digit to low double digits revenue projections for FY 25: Syngene CEO

Management expressed positive long-term outlook for the sector and expressed confidence in Syngene's sustained performance on the back of improved fund flows into US biotech in the latter part of the year.

Syngene International March quarter net profit up 6% to Rs 189 crore, revenue down 8%

Syngene's revenue in the fourth quarter of the reported financial year fell seven percent on a year-on-year basis to Rs 916.9 crore, compared to Rs 994 crore in Q4FY23

UBS downgrades Syngene to ‘sell’ on weak outlook, shares slip 3%

The outlook for Syngene looks weak on a tough marco situation, global headwinds and falling VC funding, said UBS.

Syngene: Preferred CRAMS play for the long term

The company’s underperformance, compared to the Nifty, is not justified, and there is merit in considering the stock at the current levels. In the medium term, complex APIs and biologics manufacturing would be the growth drivers.

Syngene: Stock correction serves as an opportunity to move in

The key macro headwind is the slowdown in funding in the US biotech end-market. However, in the medium term, complex APIs and biologics manufacturing would be the leading growth drivers

Syngene: Inorganic initiative to speed up biologics manufacturing bandwidth

In the medium term, complex APIs and biologics manufacturing would be leading growth drivers.

Syngene: Zoetis opportunity unfolds

Q4 FY23 aided by better-than-expected traction for the 10-year manufacturing deal with Zoetis.

Syngene: Timeline for follow-through in Zoetis contract key catalyst to watch

Another growth lever to watch in manufacturing is that of the Mangalore API facility. Here the USFDA approval is expected in H2FY24.

Syngene: Can it keep its premium valuation, going forward?

Investment in biologics is expected to remain recurring as new opportunities are unfolding in the field of biologics for Syngene

Moneycontrol Selects: Top stories this evening

Our specially curated package of the most interesting articles to help you stay at the top of your game.

Syngene: Multi-year contract with Zoetis adds to long-term visibility

The risk to watch is the execution in the field biologics and the pending regulatory approvals

Syngene International Q1 PAT slips 4% to Rs 74 crore

The company had posted a PAT of Rs 77 crore in the April-June quarter of last fiscal.